Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
144.83
+13.16 (9.99%)
At close: Apr 28, 2026, 4:00 PM EDT
144.50
-0.33 (-0.23%)
Pre-market: Apr 29, 2026, 6:02 AM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
30.46B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.24B |
| Genmab | 3.72B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
RVMD News
- 1 day ago - There's a Revolution in Cancer. But Can Big Pharma Afford It? - WSJ
- 7 days ago - Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 7 days ago - Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 days ago - Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting - GlobeNewsWire
- 11 days ago - Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 11 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff In Q2 - Benzinga